Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue Streams

Rhea-AI Summary

Synergy CHC Corp. (NASDAQ: SNYR) has expanded its international licensing agreement with Gravity Pharma to include Turkey alongside the UAE for exclusive distribution of FOCUSfactor®. The deal brings $2 million in upfront licensing revenue plus performance-based royalties from product sales in both markets. The expansion allows Synergy to scale its FOCUSfactor® brand, including brain health supplements, cognitive beverages, and energy shots, while maintaining 100% ownership and global IP. The asset-light growth strategy targets the brain health market, projected to reach $20B by 2030. The company recently strengthened its leadership team with former Coca-Cola global beverage executives to support its growth initiatives.

Positive

• Secured $2 million in upfront licensing revenue from UAE and Turkey expansion
• Additional revenue stream through performance-based royalties without operational costs
• Asset-light growth strategy maintains 100% ownership and global IP rights
• Strategic expansion into high-growth markets without capital investment
• Strengthened leadership team with former Coca-Cola executives

Negative

• None.

Insights

Consumer Health Industry Expert

Synergy's $2M UAE-Turkey FOCUSfactor® expansion secures immediate revenue while establishing presence in strategic high-growth markets with minimal capital investment.

Synergy CHC's expanded international licensing agreement represents a textbook example of capital-efficient global expansion in the competitive consumer health sector. The deal structure provides $2 million in upfront licensing payments while establishing distribution channels in two strategic emerging markets without requiring significant operational investment or infrastructure.

This expansion aligns perfectly with current industry best practices of pursuing "asset-light" growth models—generating revenue and expanding brand footprint without the traditional overhead costs of establishing direct operations in new territories. The cognitive health supplement market presents particularly attractive economics, with higher margins than many consumer health segments and projected category growth to $20 billion by 2030.

The retention of 100% IP ownership while generating licensing revenue represents significant value creation, effectively monetizing intellectual property twice—once through licensing fees and again through ongoing royalties. This structure creates immediate revenue recognition while establishing long-term royalty streams tied to market performance.

The addition of Turkey alongside UAE is strategically significant, as Turkey represents a substantially larger market (85M population versus UAE's 9.3M) with growing middle-class consumer spending on preventative health products. By leveraging Gravity Pharma's established distribution networks rather than building their own, Synergy accelerates time-to-market while transferring market-entry risk to the licensee.

This international expansion, combined with their recent executive talent acquisition from Coca-Cola, suggests a coherent growth strategy focused on brand expansion, distribution optimization, and capital efficiency—three critical success factors in scaling consumer health brands globally.

WESTBROOK, Maine, June 18, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, announced today that it has expanded its international licensing deal with Gravity Pharma, adding Turkey alongside the United Arab Emirates UAE for exclusive distribution of FOCUSfactor®. This move brings total upfront licensing revenue to $2 million, with additional performance-based royalties tied to product sales across both high-growth markets.

"This isn’t just an expansion—it’s execution," said Jack Ross, CEO of Synergy CHC Corp. “Adding Turkey alongside the United Arab Emirates (UAE), compounds our momentum and unlocks untapped growth in scalable, capital-efficient markets. We’re building brand equity globally without the overhead—exactly how growth should look in 2025.”

The UAE-Turkey licensing model allows Synergy to scale the FOCUSfactor® brand—including brain health supplements, cognitive beverages, and energy shots—without diluting ownership or diverting U.S.-based operational focus. Synergy retains 100% ownership and global IP, with performance-based royalties driving long-term upside.

Key Highlights for Investors:

• $2M in licensing secured
• Additional revenue potential through royalties
• Scalable, asset-light growth strategy
• Brain health market expected to top $20B by 2030

With global demand for cognitive health solutions surging and strategic distribution partnerships now active, SNYR is well-positioned to capitalize on both brand strength and macro health trends. These developments follow key leadership hires from Coca-Cola’s global beverage team, reinforcing the Company’s commitment to accelerated growth and operational precision.

About Synergy CHC Corp.
Synergy CHC Corp. (NASDAQ: SNYR) is a next-generation consumer health and wellness company. Its flagship brands include FOCUSfactor®, a clinically tested brain health supplement, and Flat Tummy®, a lifestyle wellness brand for women. Synergy is executing a high-margin, global expansion strategy across functional health categories through capital-efficient partnerships.

Investor Relations
Gateway Group
Cody Slach, Greg Robles
949.574.3860
SNYR@gateway-grp.com

FAQ

What is the value of Synergy CHC's (SNYR) new licensing deal for FOCUSfactor?

The licensing deal brings $2 million in upfront revenue, plus additional performance-based royalties from product sales in both UAE and Turkey markets.

Which markets is Synergy CHC (SNYR) expanding FOCUSfactor into?

Synergy CHC is expanding FOCUSfactor distribution into Turkey and the United Arab Emirates (UAE) through a licensing agreement with Gravity Pharma.

What products will Synergy CHC (SNYR) distribute in UAE and Turkey?

Synergy CHC will distribute the FOCUSfactor brand products, including brain health supplements, cognitive beverages, and energy shots.

How does the licensing model benefit Synergy CHC (SNYR) shareholders?

The model allows for revenue growth without operational costs, maintains 100% ownership and IP rights, and provides both upfront revenue and ongoing royalties without diluting ownership.

What is the market potential for Synergy CHC's (SNYR) brain health products?

The brain health market is expected to exceed $20 billion by 2030, positioning Synergy CHC to capitalize on growing global demand for cognitive health solutions.